CARTQUOL
Research type
Research Study
Full title
Patient-reported quality of life after CART Therapy for patients with relapsed/refractory diffuse large B-cell lymphoma
IRAS ID
292664
Contact name
Emma Williams
Contact email
Sponsor organisation
Cardiff and Vale University Health Board
Duration of Study in the UK
4 years, 0 months, 1 days
Research summary
Quality of life is essential when considering a persons integrated feelings (Buiting 2020). As givers of CART products within the UK we need to understand more about the quality of life of these patients and be able to collect more data on their overall journey. Mariarz et al (2019) conducted a large, phase 2, quality of life study- ‘JULIET’ which has recently been published within the British Journal of Haematology and found that patients who responded well to a CART therapy- tisagenlecleucel saw an overall improvement within their quality of life. This study is a benchmark study for research into this area.
As the first site within Wales to deliver CART therapy, Cardiff and Vale UHB are keen to explore the quality of life of our patients and will use the validated quality of life tools that were used within the JULIET study FACT-Lym and SF-36, the aim being to build on the data that has already been developed, thus supporting the evidence base. Cardiff and Vale UHB will also liaise with our colleagues within Psychology to see if there are any additions to the quality of life tools proposed that would potentially benefit the patient and the assessment.REC name
Wales REC 2
REC reference
20/WA/0344
Date of REC Opinion
15 Dec 2020
REC opinion
Further Information Favourable Opinion